GEO series

Fucoxanthin ameliorates metabolic dysfunction-associated steatohepatitis via suppression of CD36-driven fatty acid uptake

GSE326385 Homo sapiens (human) RNA-seq (gene expression) 18 samples Submitted 2026/08/05 Platform GPL34284

At a glance

RNA-seq (gene expression) · human · 18 samples

What it is: RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism: Homo sapiens (human)
Samples: 18 samples: 6 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
Data you can get: A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper: Fucoxanthin Suppresses Lipid Accumulation and Inflammatory Responses in FFA-Induced Hepatocyte Models via the EGR2-CD36 AxisMolecules (Basel, Switzerland) · 2026

Summary (written by the submitters)

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with limited treatment options. Here, we demonstrate that fucoxanthin (FUCO), a natural marine carotenoid, ameliorates MASH by targeting the EGR2-CD36 axis. In FFA-induced hepatocyte models (HepG2, Hep3B, and AML12), FUCO significantly reduced lipid accumulation and inflammatory markers without cytotoxicity.

Read the full summary ↓

Mechanistic studies revealed that FUCO specifically inhibited fatty acid uptake and transport by downregulating CD36, while TG degradation remained unaffected. RNA sequencing identified EGR2 as a master regulator induced by FFA and suppressed by FUCO. Functional validation showed that EGR2 overexpression completely blocked FUCO's lipid-lowering effects and restored CD36 expression, confirming that FUCO acts through EGR2-dependent CD36 inhibition. Bioinformatic analysis further supported EGR2-mediated regulation of CD36 via TNF and SREBF pathways. Collectively, our findings establish EGR2 as a critical molecular target for FUCO and provide mechanistic insights supporting its clinical development for MASH therapy.

Published in

Fucoxanthin Suppresses Lipid Accumulation and Inflammatory Responses in FFA-Induced Hepatocyte Models via the EGR2-CD36 Axis

Li X, Yang C, Chen Q et al. · Molecules (Basel, Switzerland) 2026 · PMID 42513107 · doi:10.3390/molecules31142423

This dataset

Open GSE326385 in finder → Find more human RNA-seq datasets →

Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE326385_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓

3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1445172 and SRA study SRP687767. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 42513107) ↗

Study design

6 conditions, mostly in triplicate

Model ×3 FUCO-0.5 ×3 FUCO-1 ×3 FUCO-2 ×3 RES ×3 Con ×2 con ×1

Supports a between-group comparison across 17 samples.

How we read this: 6 replicated groups read from 18 sample titles; they account for 17 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study

GSM9630293 Con_1 Con
GSM9630294 con_2
GSM9630295 Con_3 Con
GSM9630296 Model_1 Model
GSM9630297 Model_2 Model
GSM9630298 Model_3 Model
GSM9630299 FUCO-0.5_1 FUCO-0.5
GSM9630300 FUCO-0.5_2 FUCO-0.5
GSM9630301 FUCO-0.5_3 FUCO-0.5
GSM9630302 FUCO-1_1 FUCO-1
GSM9630303 FUCO-1_2 FUCO-1
GSM9630304 FUCO-1_3 FUCO-1
GSM9630305 FUCO-2_1 FUCO-2
GSM9630306 FUCO-2_2 FUCO-2
GSM9630307 FUCO-2_3 FUCO-2
GSM9630308 RES_1 RES
GSM9630309 RES_2 RES
GSM9630310 RES_3 RES

Datasets on a similar topic

GSE289173 Single-cell eQTL analysis identifies genetic variation underlying metabolic dysfunction-associated steatohepatitis 48 samples shares dysfunction-associated, steatohepatitis
GSE274114 Metabolic dysfunction-associated steatohepatitis reduces interferon and macrophage liver gene signatures in chronic HBV patients 39 samples shares dysfunction-associated, steatohepatitis
GSE247467 Transcriptomic characterization of circulating neutrophils isolated from patients with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). 12 samples shares dysfunction-associated, steatohepatitis
GSE334408 Resmetirom ameliorates fibrogenesis in hepatic stellate cells via thyroid hormone receptor alpha-fatty-acid amide hydrolase 1 signaling pathway 8 samples shares ameliorates, fatty
GSE326605 Bile acid uptake activates STAT signaling and impairs natural killer cells in metabolic dysfunction–associated steatohepatitis 4 samples shares steatohepatitis, uptake
GSE255312 Spatial transcriptomics landscape for liver from patients with metabolic dysfunction-associated steatohepatitis (MASH) 72 samples shares dysfunction-associated, steatohepatitis
GSE281797 Transcriptomic profiles of liver biopsies in obese patients with metabolic dysfunction-associated steatotic liver disease 94 samples shares dysfunction-associated
GSE316614 Targeting mutation-agnostic disease pathways ameliorates ciliopathy-related mesenchymal drift in RPE 69 samples shares ameliorates

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.